Company profile
ASCENTAGE PHARMA GROUP INTERNATIONAL
NASDAQ:AAPGBiotechnology: Pharmaceutical Preparations
Drug pipeline (6)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| LISAFTOCLAX | phase3 | — | 17 | active |
| OLVEREMBATINIB | phase3 | — | 10 | active |
| ALRIZOMADLIN | phase2 | — | 6 | active |
| DASMINAPANT | phase2 | — | 1 | unknown |
| PELCITOCLAX | phase1_2 | — | 7 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (52)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04568265 | phase2 | unknown | 2020-06-03 | 2022-10-31 | Ascentage Pharma Group Inc. | A Clinical Study of APG-1387 in Combination With Entecavir in Patients With Chronic Hepatitis B |
| NCT04275518 | phase1 | recruiting | 2020-07-06 | 2025-12-31 | Ascentage Pharma Group Inc. | A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS. |
| NCT06389292 | phase3 | recruiting | 2024-06-11 | 2028-05-25 | Ascentage Pharma Group Inc. | A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia |
| NCT04126681 | phase2 | completed | 2019-10-21 | 2024-08-01 | Ascentage Pharma Group Inc. | A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase |
| NCT03883100 | phase2 | unknown | 2019-04-08 | 2024-04-01 | Ascentage Pharma Group Inc. | A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Accelerated Phase With T315I Mutation |
FDA applications (0)
No records yet.